Skip to content
value.today

Acceleron Pharma Inc.

XLRNUnlisted company
No market cap data
Compare
World rank
—
no current market cap
Revenue
$93 M
For year ending December-2020
Net income
$-166 M
-179.5% margin
SEC filing
Employees
225
As of December 2019
value.today research

Acceleron Pharma Inc. in brief

Acceleron Pharma Inc. is an unlisted company in the Biotechnology industry, based in Cambridge, Massachusetts, USA. It was founded in 2003. In the year to December 2020 it had sales of $93 M and a net loss of $166 M. It employs about 225 people.

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Acceleron Pharma Inc.

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

From Wikipedia: read the full article · text available under CC BY-SA 4.0

Acceleron Pharma Inc. timeline

4 events, 2003–2019
  1. 2003
  2. 🏁
    · approximate
    Founded
  3. 2004
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2013
  6. 🔔
    · approximate
    Initial public offering on Nasdaq as XLRN
  7. 2019
  8. •
    Legal Entity Identifier issued
    LEI 529900TQRID2UY164805 registered.

Events of Acceleron Pharma Inc. from Wikidata, SEC EDGAR and the GLEIF LEI register. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

More about Acceleron Pharma Inc.

Acquisitions and changes
Taken over: the company reported a change in control and the delisting of its shares to the SEC on 22 November 2021 (Form 8-K).

Market cap history

Not enough history yet.

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
—
Price / book
—
Free cash flow yield
—
Net margin (TTM)
-179.5%
Operating margin
-180.8%
Return on equity
-19.4%
Liabilities / assets
8.3%
Revenue growth
+25.0%
R&D / revenue
188.0%
Revenue per employee
$411 K
Profit per employee
$-738 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2013: revenue —, net income $-22M—FY13Fiscal year ending Dec 2014: revenue $15M, net income $-51M$15MFY14Fiscal year ending Dec 2015: revenue $18M, net income $-64M$18MFY15Fiscal year ending Dec 2016: revenue $28M, net income $-57M$28MFY16Fiscal year ending Dec 2017: revenue $13M, net income $-108M$13MFY17Fiscal year ending Dec 2018: revenue —, net income $-119M—FY18Fiscal year ending Dec 2019: revenue $74M, net income $-125M$74MFY19Fiscal year ending Dec 2020: revenue $93M, net income $-166M$93MFY20
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2020$93M+25.0%$-167M$-166M-179.5%
Dec 2019$74M—$-136M$-125M-168.8%
Dec 2018——$-124M$-119M—
Dec 2017$13M-51.5%$-110M$-108M-804.5%
Dec 2016$28M+53.4%$-66M$-57M-205.3%
Dec 2015$18M+23.7%$-61M$-64M-353.0%
Dec 2014$15M—$-55M$-51M-350.4%
Dec 2013——$7M$-22M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2020$-130M$4M$-135M$-2.92$0.00
Dec 2019$-94M$3M$-97M$-2.38$0.00
Dec 2018$-95M$3M$-97M$-2.59$0.00
Dec 2017$-77M$4M$-81M$-2.68$0.00
Dec 2016$-45M$3M$-48M$-1.52$0.00
Dec 2015$-44M$1M$-45M$-1.92$0.00
Dec 2014$-53M$1M$-54M$-1.63$0.00
Dec 2013$-20M$0M$-20M$-4.15—

SEC filings

Official filings of Acceleron Pharma Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$93 M
Operating income
$-167 M
Net income
$-166 M

For year ending December-2020 · source: SEC filing

Balance sheet

Total assets
$932 M
Total liabilities
$77 M
Total equity
$855 M

As of December-2020

Top 1 institutional investors in Acceleron Pharma Inc.#

As of Jun 30, 2026
1 institutions held 2 shares on Jun 30, 2026. Source: SEC Form 13F filings, filed through Aug 13, 2026. Change is since the previous quarter.
The 1 largest institutional investors in Acceleron Pharma Inc.
#InstitutionShares heldChange (shares)ValueFiled
1Huntington National Bank20 (0.00%)$0 MAug 13, 2026

Insider trading at Acceleron Pharma Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
29
since
Acceleron Pharma Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Joseph S. ZakrzewskiDirectorTender in a change of control-34,499——0Form 4
filed Jay T. BackstromEVP, Research and DevelopmentTender in a change of control-21,233——0Form 4
filed Sujay KangoEVP, Chief Commercial OfficerTender in a change of control-18,509——0Form 4
filed Kemal MalikDirectorTender in a change of control-1,622——0Form 4
filed Karen L. SmithDirectorTender in a change of control-1,622——0Form 4
filed Terrence C. KearneyDirectorTender in a change of control-6,749——0Form 4
filed Kevin F. McLaughlinSVP, CFO and TreasurerTender in a change of control-10,681——0Form 4
filed Francois NaderDirectorTender in a change of control-6,749——0Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Acceleron Pharma Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Stock splits: 1-for-4 reverse split

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Acceleron Pharma Inc. scorecard#

Passes 3 of the 12 checks that could be worked out: strongest in growth (1 of 3), weakest in profitability (1 of 5). Fiscal year 2020.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth1 of 3
    • ✓Revenue grew in the newest year25.0%Revenue up 25.0% in fiscal 2020.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-2.92 vs -2.38Diluted EPS -2.92 in fiscal 2020 against -2.38 the year before (report's currency).
    • ✗Net income higher than five years earlier-$166 M-$166 M in fiscal 2020 against -$64 M in 2015.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability1 of 5
    • ✗Profitable in the newest year-$166 MNet income -$166 M in fiscal 2020.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2020.
    • ✗Operating margin above its peers' median-180.8%-180.8% against Biotechnology's median of -60.5% (243 companies).
    • ✗Return on equity above 15%-25.4%-25.4% in fiscal 2020.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-180.8%-180.8% in fiscal 2020 against -815.9% in 2017.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities14.8×Current ratio 14.85 at the end of fiscal 2020.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2020.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 2
    • ✗Pays a dividendNoNo dividends in fiscal 2020.
    • ✗Dividend per share raised five years in a row0 of 5Dividend per share raised in 0 of the five years to fiscal 2020.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Acceleron Pharma Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Acceleron Pharma Inc.: statements by fiscal year
PeriodTrendFY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016FY 2015to Dec 31, 2015FY 2014to Dec 31, 2014FY 2013to Dec 31, 2013FY 2012to Dec 31, 2012FY 2011to Dec 31, 2011
Income statement
Revenue93741413281815571581
Research and development17415410490695851363533
Selling, general and administrative86563534——————
General and administrative——3534252114148.88.1
Total costs and expenses260210138123947970504442
Operating income−167−136−124−110−66−61−557.0−2939
Interest and finance income——5.62.61.90.50.10.00.10.0
Interest expense and finance costs————000.92.11.51.8
Other non-operating income (expense)1.3125.51.69.1−3.04.2−29−3.7−2.3
Income before tax−166−125−119−108−57−64r−51r−22−3336
Income tax0.0−0.1−0.00.00.000———
Net income attributable to shareholders−166−125−119−108−57−64−51−22−3336
Earnings per share, basic-2.92-2.38-2.59-2.68-1.52-1.92-1.63-4.15-24.840.80
Earnings per share, diluted-2.92-2.38-2.59-2.68-1.52-1.92-1.63-4.15-24.840.78
Shares, weighted average (basic)———————9.42.42.3
Shares, weighted average (diluted)575246403733329.42.42.7
Dividends per share0.000.000.000.000.000.000.00———
Balance sheet
Cash and cash equivalents671238144r10021281761134065
Short-term investments179194147177119770———
Receivables—————3.63.43.62.8—
Other current assets17107.74.43.92.52.52.21.5—
Current assets89345030628514711118211944—
Property, plant and equipment7.86.87.17.05.23.13.13.74.1—
Right-of-use (leased) assets2224————————
Long-term investments7.62209695310———
Total assets93250531538924814618612449—
Accounts payable8.52.30.41.11.60.90.70.90.6—
Current liabilities6033191716149.32739—
Lease liabilities (non-current)1720————————
Total liabilities775523242237306672—
Retained earnings−877−711−587−473−364−307−244−192−291—
Shareholders' equity855449292365r22610915658−291−233
Total liabilities and equity93250531538924814618612449—
Shares outstanding60534645383332r282.4—
Cash-flow statement
Depreciation and amortization3.83.93.72.81.71.21.10.91.33.1
Share-based compensation3023252819124.82.21.21.4
Cash from operating activities−130−94−95−77r−45r−44−53−20−399.1
Capital expenditure−4.2−3.3−2.6−4.4−3.4−1.0−0.5−0.3−0.4−0.0
Cash from investing activities26−71123−64−109−109−0.5−0.3−0.4−0.0
Debt repaid————00−16−3.7−6.2−9.5
Shares issued4922480216141−0.0r129r0——
Cash from financing activities538259162201474.5117941421
Change in cash433944479r−6.7r−1496374−2530
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2021. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Acceleron Pharma Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Taken over and delisted 1 · Change in control 1 · Acquisition or sale completed 1 · Directors and officers 5 · Material agreement 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 13

Acceleron Pharma Inc.: events reported to the SEC
FiledWhat happenedFiling
Taken over and delistedChange in controlAcquisition or sale completedDirectors and officersShareholder rights changedBylaws or fiscal year changed8-K
Results announced8-K
Results announced8-K
Directors and officersMaterial agreement8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Results announced8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Directors and officersShareholder vote8-K
Results announced8-K
Directors and officers8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 22, 2021

Acquisitions and funding#

4 private funding rounds before listing

Private share sales · funding history

Private share sales of Acceleron Pharma Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2013$10 MNo. 4$10 to $50 million1equitySEC
Dec 2011$30 MNo. 3$10 to $50 million47equitySEC
Jun 2010$10 MNo. 2$10 to $50 million48equity, optionsSEC
Dec 2009$11 MNo. 1$10 to $50 million40equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by Acceleron Pharma Inc.#

$30 K spent on lobbying the US Congress and federal agencies in 2022, most often on medicare/medicaid, health issues and taxation/internal revenue code.

Lobbying, 2022
$30 K
#1,324 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2022
2026 so far
—
  • Medicare/Medicaid1 report
  • Health Issues1 report
  • Taxation/Internal Revenue Code1 report

Lobbying firms hired in 2022

SPLITOAK STRATEGIES LLC $30 K

Acceleron Pharma Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2022$30 K—1
2021$84 K$60 K10

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Acceleron Pharma”, “Acceleron Pharma, Inc” and “ACCELERON PHARMA INC”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

H-1B hiring at Acceleron Pharma Inc.#

5 labor condition applications certified in fiscal 2021 for 5 positions, at a median wage of $102 K a year.

Certified, FY2021
5
#1,202 among companies on value.today
Worker positions
5
Median wage offered
$102 K
a year, full-time
Applications filed
5
Acceleron Pharma Inc.: most frequent H-1B job titles in fiscal 2021
Job titlePositionsMedian wage offered
Associate Scientist I, Protein Biochemistry - DiscoveryBiochemists and Biophysicists2$86 K
Clinical Research Outsourcing ManagerNatural Sciences Managers1$146 K
Senior Associate, Regulatory AffairsRegulatory Affairs Specialists1$110 K
Senior Quality Control Analyst IChemists1$102 K

Where: Cambridge, MA 5

Acceleron Pharma Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202155$102 K5
FY202011$70 K1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Acceleron Pharma Inc.

How Acceleron Pharma Inc. compares in Biotechnology

  • Revenue$93 M · higher than 68% of 647
  • Net margin-179.4% · higher than 30% of 408
  • Revenue growth25.0% · higher than 64% of 438

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Acceleron Pharma Inc.🇺🇸——-179.4%+25.0%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Annual results:
For year ending December-2020
Balance sheet:
As of December-2020
Employees:
As of December 2019
Profile updated:
Nov 16, 2026

Figures from SEC filing, value.today research, Wikidata, Wikipedia, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Acceleron Pharma Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Acceleron Pharma Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Acceleron Pharma Inc.? Suggest a correction